Wird geladen...
Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Gluc...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
MDPI AG
2020-03-01
|
| Schriftenreihe: | International Journal of Molecular Sciences |
| Schlagworte: | |
| Online Zugang: | https://www.mdpi.com/1422-0067/21/7/2275 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|